Christian Schaffer

We examine the comparative importance of fixed-dose combinations (FDCs) versus combinations of MONOs (monotherapies) from the patient's perspective. In addition, we evaluate the relative importance of Mechanisms of Action (MOAs) compared to FDCs. In terms of patient satisfaction, the choice between FDC and MONO is significantly more important than the prescribed MOAs. We also examine the impact of MOAs, FDCs, and MONOs on patients' ability to manage their treatment regimen and their emotional response to therapy, satisfaction, and adherence.

The Patient Matrix (PM) model we present serves as an extended framework to elucidate the empirical significance of FDC prescribing, where applicable. These findings provide valuable insights for pharmaceutical companies to further empower patients and adopt a more patient-centric approach.